Viral Hepatitis

2014 Viral Hepatitis Year-in-Review and Looking to 2015

Ronald Valdiserri

2014 has been a year of both opportunities and challenges in the fight against viral hepatitis. In May, the World Health Assembly passed a new resolution  [PDF 151 KB] on viral hepatitis, urging member states to develop and implement coordinated, national strategies for preventing, diagnosing and treating viral hepatitis.  Our nation’s own comprehensive viral hepatitis strategy,…

FDA approves Viekira Pak to treat hepatitis C


The U.S. Food and Drug Administration today approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosis. Hepatitis C is a viral disease that causes inflammation of the liver that…

Two New Hepatitis C Resources Support Expanding Provider Capacity

Ronald Valdiserri

Two professional medical societies have recently launched initiatives to support a wider variety of health care providers in adapting to new roles and opportunities resulting from the rapidly evolving arena of hepatitis C (HCV) screening, diagnosis, and treatment. As the Viral Hepatitis Action Plan observes, providers at every level in the healthcare system can play…

The 2014 Liver Meeting – Report on Viral Hepatitis Coverage at the American Association for the Study of Liver Diseases (AASLD) Meeting


Last month, the American Association for the Study of Liver Diseases (AASLD) annual meeting  (The Liver Meeting®) took place, convening nearly 10,000 physicians, surgeons, researchers, allied health professionals and advocates from around the world to discuss the natural history, prevention, and cure of liver diseases. With the availability of new all-oral, direct-acting agents (DAAs), there…

Revised Hepatitis C (HCV)/HIV Coinfection Section of the Adult and Adolescent Antiretroviral Treatment Guidelines Released

Last week, the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents announced the release of the updated “Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.” As described in What’s New in the Guidelines, this interim revision of the guidelines features a revised section on Hepatitis C (HCV)/HIV Coinfection that emphasizes…

Conversations in 2014: HIV Care and Treatment

Ron Valdiserri and Carl Dieffenbach

As partners around the world gear up for the annual observance of World AIDS Day on December 1, we at are taking a moment to look back on some of our 2014 blog posts that we thought were particularly important.  Today, we share some of our blogs about efforts to enhance the treatment and…

Silence is Deadly: Combating the Epidemic of Viral Hepatitis


Silence=Death. That phrase was used by the advocacy group ACT UP to end the silence about the AIDS crisis in the United States. This is no less true for the issue of viral hepatitis, which claims the lives of 12,000-18,000 Americans each year. Our inactivity can fuel the spread of viral hepatitis—viruses which are largely…

Primary Care Providers: Improve Care for Patients with Viral Hepatitis with ACT-First, a Free Online CME Course


Regular readers of this blog probably know that the Centers for Disease Control and Prevention (CDC) recommends hepatitis C (HCV) screening for everyone in the demographic group in the U.S. that is most likely to be infected—people born between 1945 and 1965. In addition, the U.S. Preventive Services Task Force (USPSTF) last year upgraded its…